SEC Form 4 · accession 0001209191-19-011841
Deciphera Pharmaceuticals, Inc. · DCPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Patrick Kelly
Officer — Chief Financial Officer
Period of report
Feb 19, 2019
Accepted (ET)
Feb 20, 2019 · 8:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001654151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 19, 2019 | M | 1,500 | $1.89 | A | 1,500 | D | |
| Common Stock | Feb 19, 2019 | S | 1,500 | $30.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.89 | Feb 19, 2019 | M | 1,500 | D | — | Dec 17, 2025 | Common Stock | 1,500 | 166,508 | D |
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates.